EP2981829A4 - Anti-mucin antibodies for early detection and treament of pancreatic cancer - Google Patents

Anti-mucin antibodies for early detection and treament of pancreatic cancer

Info

Publication number
EP2981829A4
EP2981829A4 EP14778990.3A EP14778990A EP2981829A4 EP 2981829 A4 EP2981829 A4 EP 2981829A4 EP 14778990 A EP14778990 A EP 14778990A EP 2981829 A4 EP2981829 A4 EP 2981829A4
Authority
EP
European Patent Office
Prior art keywords
treament
pancreatic cancer
early detection
mucin antibodies
mucin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14778990.3A
Other languages
German (de)
French (fr)
Other versions
EP2981829A1 (en
Inventor
Donglin Liu
David V Gold
Chien-Hsing Chang
Serengulam V Govindan
David M Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/036,765 external-priority patent/US8795662B2/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of EP2981829A1 publication Critical patent/EP2981829A1/en
Publication of EP2981829A4 publication Critical patent/EP2981829A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14778990.3A 2013-04-01 2014-04-01 Anti-mucin antibodies for early detection and treament of pancreatic cancer Withdrawn EP2981829A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361807176P 2013-04-01 2013-04-01
US201361818708P 2013-05-02 2013-05-02
US14/036,765 US8795662B2 (en) 2002-06-14 2013-09-25 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US201361896909P 2013-10-29 2013-10-29
PCT/US2014/032513 WO2014165506A1 (en) 2013-04-01 2014-04-01 Anti-mucin antibodies for early detection and treament of pancreatic cancer

Publications (2)

Publication Number Publication Date
EP2981829A1 EP2981829A1 (en) 2016-02-10
EP2981829A4 true EP2981829A4 (en) 2016-10-26

Family

ID=51659171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14778990.3A Withdrawn EP2981829A4 (en) 2013-04-01 2014-04-01 Anti-mucin antibodies for early detection and treament of pancreatic cancer

Country Status (4)

Country Link
EP (1) EP2981829A4 (en)
CN (1) CN105074469A (en)
CA (1) CA2899811A1 (en)
WO (1) WO2014165506A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948013A1 (en) * 2014-06-30 2016-01-07 Immunomedics, Inc. Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
CN105738492B (en) * 2014-12-10 2017-12-19 人福医药集团股份公司 The method of impurity content in LC MS/MS combination measure Lapatinibs
CA2983311A1 (en) * 2015-04-20 2016-10-27 Minomic International Ltd. Therapeutic antibodies and uses thereof
US10912767B2 (en) 2015-04-27 2021-02-09 The Regents Of The University Of Colorado, A Body Corporate Anthracycline prodrugs and methods of making and using the same
WO2017007807A1 (en) * 2015-07-07 2017-01-12 Immunomedics, Inc. IMPROVED METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES
AU2016361350B2 (en) * 2015-11-23 2023-04-06 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
CN107362370B (en) * 2016-05-13 2022-07-26 国家纳米科学中心 Method for treating pancreatic cancer based on combination of gold nanoclusters and NGF siRNA
PL3458101T3 (en) * 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Protac antibody conjugates and methods of use
CN107153908A (en) * 2017-03-24 2017-09-12 国家计算机网络与信息安全管理中心 Mobile news App influence power ranking methods
CN113198018A (en) * 2021-04-30 2021-08-03 张志刚 Application of targeted leukotriene receptor in pancreatic cancer treatment composition
CN116804221B (en) * 2023-08-23 2023-11-03 汲迈生命科技(苏州)有限公司 Application of LMO7 expression level in prediction of pancreatic cancer gemcitabine resistance
CN117275744B (en) * 2023-11-22 2024-02-13 北京大学人民医院 Method for constructing lung cancer prognosis multi-mode prediction model by combining gene mutation characteristics and mIF image characteristics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091113A2 (en) * 2010-01-22 2011-07-28 Immunomedics, Inc. Detection of early-stage pancreatic adenocarcinoma
WO2012112443A2 (en) * 2011-02-15 2012-08-23 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0311799A (en) * 2002-06-14 2005-05-10 Immunomedics Inc Hpam4 Monoclonal Antibody
US9005613B2 (en) * 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
EP2331134A4 (en) * 2008-08-08 2014-10-15 Immunomedics Inc Anti-pancreatic cancer antibodies
US20130005598A1 (en) * 2009-12-31 2013-01-03 The Regents Of The University Of Michigan Methods for Diagnosing The Malignant Potential of Pancreatic Cystic Lesions
WO2011133609A2 (en) * 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
JP6157352B2 (en) * 2010-10-08 2017-07-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Monoclonal antibody framework binding interface for meditope, meditope delivery system, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091113A2 (en) * 2010-01-22 2011-07-28 Immunomedics, Inc. Detection of early-stage pancreatic adenocarcinoma
WO2012112443A2 (en) * 2011-02-15 2012-08-23 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. V. GOLD ET AL: "Detection of Early-Stage Pancreatic Adenocarcinoma", CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION, vol. 19, no. 11, 1 September 2010 (2010-09-01), pages 2786 - 2794, XP055062254, ISSN: 1055-9965, DOI: 10.1158/1055-9965.EPI-10-0667 *
See also references of WO2014165506A1 *

Also Published As

Publication number Publication date
WO2014165506A1 (en) 2014-10-09
EP2981829A1 (en) 2016-02-10
CA2899811A1 (en) 2014-10-09
CN105074469A (en) 2015-11-18

Similar Documents

Publication Publication Date Title
IL272905A (en) Methods of treating pancreatic cancer
EP2981829A4 (en) Anti-mucin antibodies for early detection and treament of pancreatic cancer
HK1214652A1 (en) Methods and compositions for detecting pancreatic cancer
HK1220473A1 (en) Anti-alpha-synuclein antibodies and methods of use --
SG11201604743QA (en) Cancer detection method using sense of smell of nematode
GB201318390D0 (en) Opto-physiological sensor and method of design
GB201320061D0 (en) Materials nad methods for diagnosis and prognosis of liver cancer
EP2675485A4 (en) Anti-mucin antibodies for early detection and treatment of pancreatic cancer
SG11201510701QA (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
EP2967429A4 (en) Methods and apparatus for enhanced detection of diseases
IL244590A0 (en) Anti-epcam antibodies and methods of use
HK1213634A1 (en) Methods of detecting cancer
HK1214183A1 (en) Methods and materials for detection of biologicals
HK1211322A1 (en) Methods of treating pancreatic cancer
HK1220253A1 (en) Methods of detecting prostate cancer
HK1205558A1 (en) Methods and biomarkers for detection and prognosis of cervical cancer
IL245037A0 (en) Treatment for pancreatic cancer
GB201314485D0 (en) Materials and methods relating to pancreatic cancer
IL241290A0 (en) Sovaprevir polymorphs and methods of manufacture thereof
GB2531169B (en) Method for determining degree of modified potency of bipathic medicament
PL3065751T3 (en) Method for treatment of cancer and cancer comorbidities
EP3006942A4 (en) Reagent including anti-lgr6 antibodies for detection and diagnosis of cancer
GB201315195D0 (en) Identifying presence of substances
HK1214502A1 (en) Combination of ro5503781 and capecitabine for cancer therapy ro5503781
GB201508185D0 (en) Methods of detecting and predicting cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160923

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20160919BHEP

Ipc: G01N 33/574 20060101AFI20160919BHEP

Ipc: C07K 16/30 20060101ALI20160919BHEP

Ipc: C07K 16/44 20060101ALI20160919BHEP

17Q First examination report despatched

Effective date: 20171017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180501